脂质体作为溶栓药物载体靶向抗血栓的实验研究  

Liposomes as Carrier of Thrombolysis Medicine Against Thrombus

作　　者：王红霞[1] 杨慧[1] 郝刚[1] 曾翔俊[1] 芦玲巧[1] 江瑛[1] 朱宪[1] 姚兴海[1] 张立克[1] 

机构地区：[1]首都医科大学病理生理学教研室

出　　处：《首都医科大学学报》2004年第3期290-293,共4页Journal of Capital Medical University

基　　金：北京市教委科技发展计划 ( 99KJ 15 )资助项目

摘　　要：为观察血小板膜蛋白受体拮抗剂RGDS肽 (精 甘 天冬 丝氨酸肽 )作为溶栓的归巢装置 ,连接包有溶栓剂的脂质体 (LIP)的溶栓效果 ,用FeCl3复制腹主动脉血栓模型 ,各组自股静脉滴注 :①缓冲液 (PBS) ;② 5 .2万IU/kg尿激酶 (UKl) ;③ 1 5 .6万IU/kg尿激酶 (UKh) ;④ 5 .2万IU/kg尿激酶、脂质体与RGDS的混合物 (ULR) ;⑤包裹 5 .2万IU/kg尿激酶的脂质体与RGDS的混合物 (U LR) ;⑥包裹 5 .2万IU/kg尿激酶的脂质体与RGDS偶连物 (U L R)。发现 :UKh组和U L R组的血压与其他各组相比差异有显著性 (P <0 .0 5 )。ULR组〔( 2 7.1± 5 .7)mg〕及U LR组〔( 2 6.6± 6.1 )mg〕的血栓湿质量与U L R组〔( 2 0 .3± 5 .1 )mg〕相比差异有显著性 (P <0 .0 5 )。UKh及U L R组与其他各组相比血栓缩小。提示 :脂质体作为溶栓药物载体 ,经RGDS修饰后 ,具有较好的靶向性抗血栓作用。The aim was to observe the effects of liposomes containing thrombolysis dosage connected with blood platelet membrane glycoprotein as thrombolysis homing equipment on dissolving thrombus. The common abdomenal artery thrombus model was established with FeCl 3. Different thrombolysis dosage was from femoral vein: ①buffer(PBS), ②5.2×10 4 IU/kg urokinase (UKl), ③15.6×10 4 IU/kg urokinase, ④5.2×10 4 IU/kg mixture of urokinase, liposomes and RGDS, ⑤ The mixture of liposomes encapsulating 5.2×10 4 IU/kg urokinase and RGDS, ⑥ the coupler of liposomes and RGDS enwrapping 5.2×10 4 IU/kg urokinase. Blood pressure, wet weight of thrombus and morphologic changes in UKh and U-L-R groups differed greatly from other groups. The results show liposomes as the carrier of medicine has better target anti-thrombus effect after RGDS modifies it.

关 键 词：脂质体 尿激酶 UK 溶栓药物 靶向 抗血栓 实验研究 载体 丝氨酸 归巢 

分 类 号：R542.22[医药卫生—心血管疾病] R743[医药卫生—内科学]